Regencell Bioscience Holdings (RGC) Operating Leases (2022 - 2025)

Regencell Bioscience Holdings' Operating Leases history runs 4 years deep, the most recent figure standing at $128178.0 for Q4 2025.

• Quarterly Operating Leases changed N/A year-over-year to $128178.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $128178.0 (changed N/A YoY) and the FY2025 annual result came in at $231635.0, up 793.17% from the prior year.
• Operating Leases was $128178.0 for Q4 2025 at Regencell Bioscience Holdings, down from $231635.0 in the prior quarter.
• Across five years, Operating Leases topped out at $771255.0 in Q2 2022 and bottomed at $25406.0 in Q2 2023.
• A 4-year average of $236481.6 and a median of $128178.0 in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases plunged 96.71% — and 2025, when it jumped 793.17%.
• Regencell Bioscience Holdings' Operating Leases stood at $771255.0 in 2022, then plunged by 96.71% to $25406.0 in 2023, then gained by 2.08% to $25934.0 in 2024, then soared by 394.25% to $128178.0 in 2025.
• Business Quant data shows RGC's Operating Leases at $128178.0 in Q4 2025, $231635.0 in Q2 2025, and $25934.0 in Q2 2024.